Vaxil Bio overachieving stated CoronaVirus Vaccine timelines Starting: NESS-ZIONA, ISRAEL – February 18, 2020 – VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide further update to the Company’s press release dated February 13, 2020 on the possible identification of a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). AND recognized by the World Health Organization which gives complete legitimacy ( ability to be defended with logic or justification; validity.)
During the next quarter, Vaxil plans to initiate non-GMP manufacturing. The non-GMP product will be made available for pre-clinical testing by those who express interest and qualify. In addition, Vaxil will explore partnerships and other possibilities to test the vaccine and if successful to bring to patients worldwide as expeditiously as possible.
NESS-ZIONA, ISRAEL – March 10, 2020 – VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has submitted a new patent application for its anti-infective vaccines platform as a result of our recently announced COVID19 candidate discovery.
NESS-ZIONA, ISRAEL – March 27, 2020 – VAXIL BIO LTD
In February 2020 we announced that we believed that we had successfully identified a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHitTM bioinformatics platform. The Vaccine Candidate is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine.
We are now pleased to announce that we have non-GMP vaccine material in hand and have begun to execute our preclinical program to test the efficacy of our COVID-19 vaccine candidate.
Also,
In early March 2020, we announced our applications for a US patent (U.S 62/987,310) on a coronavirus vaccine intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing infectious disease as well as methods for producing a peptide vaccine against coronaviruses.
We are now also pleased to announce that today, Vaxil has applied for an additional patent in connection with COVID-19. An application for a US patent was filed on March 26, 2020 that is intended to provide coverage for a broader set of vaccine candidates.
Stop the yelling nonsense please !